Stem cell transplants cut MS relapses more than two drugs
Key Takeaway
In matched groups with relapsing MS, stem cell transplants were linked to fewer relapses and more disability improvement than Mavenclad or Lemtrada.
What They Found
Researchers compared stem cell transplant with cladribine (Mavenclad) and alemtuzumab (Lemtrada) in separate groups. People who received transplants had fewer relapses than those taking either drug. They were also more likely to show improvement on a disability scale. Disability worsening was similar across the treatments. About 34% of transplant recipients had delayed complications, mainly infections; no treatment-related deaths were reported.
Who Should Care and Why
The study included people with relapsing-remitting MS who had active disease and moderate disability. They received a stem cell transplant, Mavenclad, or Lemtrada. The researchers matched people with similar health and personal characteristics before comparing their outcomes. The findings speak to relapses and changes in disability after these treatments. They also report delayed complications after transplant.
Important Considerations
You should know this was a study of treatment records, not a trial that randomly assigned treatments. The abstract gives group sizes for two comparisons, but not a total count of unique people. You cannot tell from this study whether unmeasured differences between groups affected the results.
AI-generated summary — for informational purposes only, not medical advice
Categories:
Article Topics:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
11/1/2026
In a study of 294 pregnancies, MS flare-ups were uncommon after pausing two treatments. Learn what t
Read More
10/9/2026
A mouse study suggests prepared red blood cells may calm MS-like immune attacks. Learn why liver cel
Read More
10/9/2026
See how lab-grown nerve cells move a key protein, why this may matter for nerve health, and why the
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Brain : a journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.